trem-1

FDA Grants Fast Track to Nangibotide for Septic Shock

Inotrem S.A. announced that the FDA has granted Fast Track designation to nangibotide (LR12) for septic shock treatment. This TREM-1 inhibitor shows potential as the first mechanism-based therapy for the condition, which has a 35% mortality rate in developed countries. Phase IIa trial results support its safety and activity in selected patients.